Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...

Pharmacokinetics in Pediatric Patients: Drug Metabolism

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...

Drug Dosing: Infants and Children

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...

Pharmacokinetics in Pediatric Patients: Drug Distribution

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...

Pharmaceutical Poisoning: Potential Scenarios

Pharmaceutical Poisoning: Potential Scenarios

Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Why are certain age bands used for children in paediatric studies of medicines?

Archives of disease in childhood·2021

Same author

Antimicrobial consumption in a tertiary children's hospital in Finland (2003-2013).

European journal of hospital pharmacy : science and practice·2019

Same author

Increased acetaminophen related calls to Finnish PIC better reflect acetaminophen sales than serious poisonings.

Clinical toxicology (Philadelphia, Pa.)·2017

Same author

Off-label use of antimicrobials in neonates in a tertiary children's hospital.

European journal of clinical pharmacology·2017

Same author

Data monitoring committees should be used more frequently and appropriately to monitor paediatric clinical trials, particularly those involving neonates.

Acta paediatrica (Oslo, Norway : 1992)·2016

Same author

How to optimise drug study design: pharmacokinetics and pharmacodynamics studies introduced to paediatricians.

The Journal of pharmacy and pharmacology·2016

Search research articles

Related Experiment Video

Updated: May 11, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Reflection: medicines for children--science alone is not enough.

¹Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland. kaarlo.hoppu@hus.fi

European Journal of Clinical Pharmacology

|May 4, 2013

Summary

Ensuring children receive needed medicines globally is challenging, especially in poorer nations. Advocacy and collaboration were crucial in adopting the "Better medicines for children" resolution, highlighting science

More Related Videos

Whole-body PET/MRI of Pediatric Patients: The Details That Matter

Whole-body PET/MRI of Pediatric Patients: The Details That Matter

Published on: December 19, 2017

Related Experiment Videos

Last Updated: May 11, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Whole-body PET/MRI of Pediatric Patients: The Details That Matter

Whole-body PET/MRI of Pediatric Patients: The Details That Matter

Published on: December 19, 2017

Area of Science:

Global Health
Pediatric Pharmacology
Medicines Access

Background:

Access to essential medicines for children's health needs is a persistent global issue.
This problem disproportionately affects middle- and low-income countries where the majority of the world's children reside.
Previous initiatives in the USA and European Union aimed to address pediatric medicine access.

Purpose of the Study:

To highlight the global challenge of providing adequate medicines for children's therapeutic requirements.
To underscore the particular difficulties faced by middle- and low-income countries in pediatric medicine access.
To document the process and factors contributing to the adoption of a global pediatric medicines initiative.

Main Methods:

The study describes the global pediatric and pediatric clinical pharmacology community's desire for a World Health Organization (WHO) initiative.
It notes the WHO's initial resistance to involvement in a dedicated pediatric medicines program.
The process involved advocacy, networking, cooperation, persistence, and some luck to achieve the resolution.

Main Results:

The advocacy efforts culminated in the adoption of the "Better medicines for children" resolution 60.20 by the World Health Assembly in May 2007.
This resolution marked a significant step towards improving access to pediatric medicines globally.
The success required more than scientific advancement, involving concerted collaborative efforts.

Conclusions:

Scientific advancements were instrumental in the developments leading to and following the pediatric initiatives.
However, the World Health Organization's example demonstrates that science alone is insufficient to drive necessary change.
Sustained advocacy, collaboration, and persistence are vital for global health policy implementation.